bluebird bio (BLUE) Stock Forecast & Price Target

$0.29 -0.01 (-3.23%)

(As of 09:33 AM ET)

bluebird bio - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 11 Analyst Ratings

Sell
2

Hold
7

Buy
2

Based on 11 Wall Street analysts who have issued ratings for bluebird bio in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 2 have given a sell rating, 7 have given a hold rating, and 2 have given a buy rating for BLUE.

Consensus Price Target

$3.03
931.72% Upside

According to the 11 analysts' twelve-month price targets for bluebird bio, the average price target is $3.03. The highest price target for BLUE is $7.00, while the lowest price target for BLUE is $0.50. The average price target represents a forecasted upside of 931.72% from the current price of $0.29.

Get the Latest News and Ratings for BLUE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for bluebird bio and its competitors.

BLUE Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	6 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	5 Hold rating(s)
Sell	2 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$3.03	$4.63	$4.74	$7.62
Forecasted Upside	931.72% Upside	816.22% Upside	588.90% Upside	101.08% Upside
Consensus Rating	Hold	Hold	Hold	Hold

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Claim your FREE 2024 Gold Guide

BLUE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BLUE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

bluebird bio Stock vs. The Competition

Type	bluebird bio	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	898.35% Upside	26,931.55% Upside	9.81% Upside
News Sentiment Rating	Neutral News See Recent BLUE News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Royal Bank of Canada 4 of 5 stars	Reiterated Rating	Sector Perform ➝ Sector Perform	$4.00 ➝ $4.00	+1,142.59%
11/15/2024	Barclays 3 of 5 stars	Lower Target	Overweight ➝ Overweight	$4.00 ➝ $2.00	+502.58%
11/15/2024	JPMorgan Chase & Co. 3 of 5 stars	Downgrade	Neutral ➝ Underweight
11/15/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$3.00 ➝ $0.50	+37.89%
9/25/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$3.00 ➝ $2.00	+315.36%
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
Get the Latest News and Ratings for BLUE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.
8/15/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$7.00 ➝ $6.00	+636.28%
3/19/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$1.72 ➝ $1.68	+16.67%
3/5/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Reduce ➝ Reduce	$2.31 ➝ $1.02	-33.33%
1/9/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
12/8/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$3.00 ➝ $7.00	+45.53%
11/8/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$10.00 ➝ $13.00	+267.23%
1/23/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform	$9.00 ➝ $8.00	+29.24%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:53 AM ET.

BLUE Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for bluebird bio is $3.03, with a high forecast of $7.00 and a low forecast of $0.50.
: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
: According to analysts, bluebird bio's stock has a predicted upside of 931.72% based on their 12-month stock forecasts.
: Over the previous 90 days, bluebird bio's stock had 2 downgrades by analysts.
: bluebird bio has been rated by research analysts at Bank of America, Barclays, Cantor Fitzgerald, JPMorgan Chase & Co., Royal Bank of Canada, and Wells Fargo & Company in the past 90 days.
: Analysts like bluebird bio less than other "medical" companies. The consensus rating for bluebird bio is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BLUE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

Claim your FREE 2024 Gold Guide

This page (NASDAQ:BLUE) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

bluebird bio (BLUE) Stock Forecast & Price Target